According to an NBC News report, the Institute for Clinical and Economic Review (ICER), an independent, non-profit organization that analyzes clinical and cost effectiveness in new medicines, has taken issue with the price of two recently approved cholesterol drugs. The medications, which belong to a new class of cholesterol drugs called proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, are Sanofi and Regeneron’s Praluent and Amgen’s Repatha. ...
continue reading...Review Group Says New Cholesterol Drugs Too Expensive
Posted October 4, 2015 in Drug and Medical Device Lawsuits | Product News and Recalls